92 related articles for article (PubMed ID: 25831456)
1. Platelet Count After Chemotherapy is a Predictor for Outcome for Ovarian Cancer Patients.
Eggemann H; Ehricke J; Ignatov T; Fettke F; Semczuk A; Costa SD; Ignatov A
Cancer Invest; 2015 May; 33(5):193-6. PubMed ID: 25831456
[TBL] [Abstract][Full Text] [Related]
2. Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second-line chemotherapy.
Nather A; Mayerhofer K; Grimm C; Hefler L; Leodolter S; Obermair A; Joura EA
Anticancer Res; 2003; 23(3C):2991-4. PubMed ID: 12926151
[TBL] [Abstract][Full Text] [Related]
3. A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors.
Todenhöfer T; Renninger M; Schwentner C; Stenzl A; Gakis G
BJU Int; 2012 Dec; 110(11 Pt B):E533-40. PubMed ID: 22578156
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of thrombocytosis in ovarian cancer.
Słabuszewska-Jóźwiak A; Dmoch-Gajzlerska E; Kozakiewicz B; Jakiel G
Ann Agric Environ Med; 2015; 22(4):731-5. PubMed ID: 26706987
[TBL] [Abstract][Full Text] [Related]
5. Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer.
Hu Q; Hada A; Han L
J Ovarian Res; 2020 Jul; 13(1):78. PubMed ID: 32682445
[TBL] [Abstract][Full Text] [Related]
6. Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer.
Bozkurt N; Yuce K; Basaran M; Kose F; Ayhan A
Obstet Gynecol; 2004 Jan; 103(1):82-5. PubMed ID: 14704249
[TBL] [Abstract][Full Text] [Related]
7. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
[TBL] [Abstract][Full Text] [Related]
8. [Correlation between platelet count and CA-125 in ovarian cancer].
Friebe Z; Watrowski R; Bembnista M; Rokowska A; Włosiińska J; Dembińska M
Ginekol Pol; 2005 Mar; 76(3):187-94. PubMed ID: 16018136
[TBL] [Abstract][Full Text] [Related]
9. Differential platelet levels affect response to taxane-based therapy in ovarian cancer.
Bottsford-Miller J; Choi HJ; Dalton HJ; Stone RL; Cho MS; Haemmerle M; Nick AM; Pradeep S; Zand B; Previs RA; Pecot CV; Crane EK; Hu W; Lutgendorf SK; Afshar-Kharghan V; Sood AK
Clin Cancer Res; 2015 Feb; 21(3):602-10. PubMed ID: 25473001
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
11. Thrombocytosis as a prognostic factor in endometrial carcinoma.
Gücer F; Moser F; Tamussino K; Reich O; Haas J; Arikan G; Petru E; Winter R
Gynecol Oncol; 1998 Aug; 70(2):210-4. PubMed ID: 9740692
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract][Full Text] [Related]
13. Thrombocytosis in advanced epithelial ovarian cancer.
Soonthornthum T; Suraseraneewong V; Kengsakol K; Wijaithum K; Kasemsan P; Prommatt S
J Med Assoc Thai; 2007 Aug; 90(8):1495-500. PubMed ID: 17926975
[TBL] [Abstract][Full Text] [Related]
14. Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis.
Lin MS; Huang JX; Zhu J; Shen HZ
Hepatogastroenterology; 2012 Sep; 59(118):1687-90. PubMed ID: 22591645
[TBL] [Abstract][Full Text] [Related]
15. [Effects of platelet and fibrinogen on progressive ovarian cancer].
Li CY; Wu M; Yuan JY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Feb; 31(1):81-3. PubMed ID: 19317067
[TBL] [Abstract][Full Text] [Related]
16. Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies.
Menczer J
Arch Gynecol Obstet; 2017 Jan; 295(1):9-15. PubMed ID: 27714462
[TBL] [Abstract][Full Text] [Related]
17. The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer.
Baranyai Z; Krzystanek M; Jósa V; Dede K; Agoston E; Szász AM; Sinkó D; Szarvas V; Salamon F; Eklund AC; Szállási Z; Jakab F
Thromb Haemost; 2014 Mar; 111(3):483-90. PubMed ID: 24285160
[TBL] [Abstract][Full Text] [Related]
18. Thrombocytosis as a predictor of distant recurrence in patients with rectal cancer.
Cravioto-Villanueva A; Luna-Perez P; Gutierrez-de la Barrera M; Martinez-Gómez H; Maffuz A; Rojas-Garcia P; Perez-Alvarez C; Rodriguez-Ramirez S; Rodriguez-Antezana E; Ramirez-Ramirez L
Arch Med Res; 2012 May; 43(4):305-11. PubMed ID: 22727694
[TBL] [Abstract][Full Text] [Related]
19. Macrophage colony-stimulating factor enhances platelet recovery following cisplatin/carboplatin chemotherapy in ovarian cancer.
Suzuki M; Ohwada M; Aida I; Sato I; Tamada T
Gynecol Oncol; 1994 Jul; 54(1):23-6. PubMed ID: 8020834
[TBL] [Abstract][Full Text] [Related]
20. Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records.
Cozzi GD; Samuel JM; Fromal JT; Keene S; Crispens MA; Khabele D; Beeghly-Fadiel A
BMC Cancer; 2016 Aug; 16():612. PubMed ID: 27502272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
